^
Association details:
| Biomarker: | EGFR L861Q |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | EGFR inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Survival analysis of patients with advanced non-small cell lung cancer receiving EGFR-TKI treatment of Yunnan in southwestern China: a real-world study
Published date:
10/26/2023
Excerpt:
This study aimed to investigate the clinical impact of histologic type on the survival outcomes of patients with stage IIIB and IV NSCLC receiving EGFR-TKI treatment of Yunnan in southwestern China....Notably, subgroup analysis of our study also found that PFS was significantly better in patients with G719X, L861Q, S768I, G719X+L861Q, and G719X+S768I in Xuanwei than classical mutation ones, including 19-Del and L858R (median 22.7 vs. 12.0 months, HR=0.523, P=0.010)...
DOI:
10.3389/fonc.2023.1156647
Source:
Title:
Effectiveness of EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer patients with uncommon EGFR mutations: A multicenter observational study
Published date:
10/29/2020
Excerpt:
The overall response rate (RR) and disease control rate (DCR) of NSCLC patients with uncommon EGFR mutations who received first EGFR‐TKI therapy was 59.1% and 81.8%, respectively (Table 2). A total of 13 patients exhibited partial response (PR). Within the single mutation subcategory, nine out of 13 patients with G719X mutation (RR = 69.2%, DCR = 84.6%) and two out of four patients with L861Q mutation (RR = 50.0%, DCR = 100%) exhibited PR.
DOI:
https://doi.org/10.1111/1759-7714.13718
